Medistem Acquires Worldwide Patent Pending Rights to Potential Stem Cell Treatment for a Variety of Cancers; Proprietary Stem Cell Technology has Demonstrated Ability to Trigger Cancer Cells to Behave Like Normal Cells.

SCOTTSDALE, Ariz. -- Medistem Laboratories, Inc. (OTCBB:MDSM)(FWB:S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, announced it has acquired exclusive worldwide rights to a potential treatment for cancer that uses stem cells to reprogram malignant cells to behave like normal cells.

The patent pending technology has the potential to lead to the development of anticancer treatments for a variety of the most serious and widespread cancers. The invention was discovered by Dr. Thomas Ichim, a Medistem consultant.

"This new patent pending strengthens Medistem's intellectual property portfolio," said Neil Riordan, Ph.D., CEO of Medistem. "It is an example of the promise of stem cell-based technology to enable the creation of medical therapies that could revolutionize the treatment of cancer and other serious medical conditions."

The technology described in the patent application focuses on stem cell therapies that have demonstrated anticancer effects by inducing cancer cells to differentiate into benign, non-malignant cells. The patent pending pertains specifically to the use of stem cells derived from adult sources, such as umbilical cords and placentas from healthy, full-term births.

Medistem believes the newly acquired patent pending may provide doctors and cancer patients with an entirely new avenue of treatment options. "While chemotherapy and radiation therapy induce severe side effects through collateral damage to non-cancerous cells and organs, the present invention utilizes the ability of cancer cells to be 'reprogrammed' into benign, non-cancerous progeny," said Dr. Ichim.

Recently published research conducted at Northwestern University with federally approved human embryonic stem cell lines has demonstrated the ability of stem cells to successfully reprogram malignant melanoma cells into cells that behave like normal skin cells. This work adds credence to the newly acquired patent pending.

About Medistem Laboratories, Inc.

Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The Company intends to create these treatments from adult stem cells derived from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, but not the controversial embryonic or fetal stem cells that are the focus of ethical and moral debates in some communities. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients. Initial development and treatment focus will use proprietary technology and cells sourced from umbilical cords, fat, bone marrow, and muscle for advanced treatment of cerebral palsy, stroke, cardiovascular disease and orthopedic diseases, primarily for the international marketplace. Additional applications, ultimately be targeted to the treatment of neurological disorders such as Parkinson's, Alzheimer's and certain types of cancer. Medistem believes it may hold a substantial competitive edge in the worldwide emerging market for stem cell-sourced medical solutions, positioning it to become a leading global provider of stem cell treatments on a fee-for-service basis, while accumulating intellectual property based on clinical and laboratory findings. For more information, please visit http://www.trilogy-capital.com/tcp/medistem/. To read or download Medistem's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/medistem/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/medistem/quote.html. Medistem is traded on the Frankfurt, Germany, stock exchange under the symbol S2U.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward looking statements contained herein can be identified by the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates," or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements that are not historical facts, are only predictions. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved.